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J. H. Frederik Falkenburg,1 Edus H. Warren2INTRODUCTION T cells [1]. DLI can produce complete remissions inAllogeneic hematopoietic stem cell transplantation
(alloSCT) can produce durable remissions in many
patients suffering from hematologic malignancies. The
elimination of malignant cells after the transplant was
initially thought to be attributable to the myeloablative
chemotherapy and irradiation administered during the
procedure, and infusion of hematopoietic stem cells
was necessary to restore normal hematopoiesis. Autolo-
gous hematopoietic cell grafts or grafts derived from an
identical twin were felt to provide the optimal source of
hematopoietic stem cells for transplantation, because
the use of grafts from allogeneic donors was associat-
ed with immunologic complications including severe
graft-versus-host disease (GVHD).However, the devel-
opment of GVHDwas associated with a decreased like-
lihood of posttransplant relapse—leading to the concept
of a graft-versus-leukemia (GVL) effect. Depletion of
T cells from the hematopoietic cell graft decreased the
risk ofGVHD, butwas also associatedwith an increased
risk of posttransplant relapse, suggesting that T cells
play a crucial role in the development of both GVHD
and GVL. Moreover, transplantation with a T cell-
replete graft from an identical twin was not associated
with a significant GVL effect, demonstrating that the
mere presence of T cells in hematopoietic stem cell
grafts is not sufficient to mediate GVL activity, and
that genetic disparity between donor and recipient is
required for a significant antitumor effect.
Durable remissions of persistent or relapsed leuke-
mia after donor lymphocyte infusion (DLI) provided
direct evidence for a GVL effect mediated by donor1Leiden University Medical Center, Leiden, The Nether-
and 2Fred Hutchinson Cancer Research Center, Seattle,
ington.
isclosure: See Acknowledgments on page S37.
dence and reprint requests: J.H.F. Falkenburg,MD, PhD,
tment of Hematology, Leiden University Medical Cen-
.O. Box 9600, C2-R. 2300 RC Leiden, The Netherlands
il: falkenburg.hematology@lumc.nl).
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.11.00920% to 80% of patients, with the success rate highly
dependent on the underlying malignancy. Chronic
myeloid leukemia (CML) in chronic phase is highly sus-
ceptible to DLI. Although the success rate is much
lower, and additional chemotherapy and/or antibody
administration may be required in patients with other
hematologic malignancies, patients treated for relapsed
acute myeloid leukemia (AML), multiple myeloma
(MM), chronic lymphocytic leukemia (CLL), or non-
Hodgkin’s lymphoma (NHL), and some patients with
acute lymphoblastic leukemia (ALL), may also show
profound clinical responses. The striking therapeutic
efficacy of DLI demonstrated unequivocally that
donor-derived T cells recognizing alloantigens on the
recipient’s tumor cells can mediate curative GVL
reactivity.
Improving the outcome of alloSCT will require
the development of effective strategies for separating
GVHD from GVL [2]. Host conditions, timing, and
cell dose all influence the efficacy of DLI. Depletion
of donor T cells from the graft followed by delayed
administration of donor T cells after hematopoietic
recovery in the recipient appears to decrease the
incidence of GVHD while preserving GVL activity.
Murine and human studies illustrating that the micro-
environment in recipient tissues plays an important
role in GVHD development provided the rationale
for this approach. Tissue damage caused by the condi-
tioning regimen leading to presentation of cellular
debris by antigen presenting cells in the context of
danger signals provided by pathogens may lead to
the initiation of a cytokine storm that amplifies the
donor antihost response.
Lymphocyte depletion in the early posttransplant
period produced by the conditioning regimen likely
leads to homeostatic proliferation of donor T cells
and thus to increased antihost reactivity. The balance
between patient- and donor-derived activated den-
dritic cells (DC), which are required for the induction
of alloimmune responses, strongly influences the bal-
ance between limited or extensive GVHD. Absence
of immunostimulatory cells in the microenvironment
following transplantation may abrogate alloimmune
responses, resulting in the persistence of malignantS33
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the administration of large numbers of donor T cells.
Donor T cells recognizing recipient alloantigens
are the central, albeit not exclusive, mediators of
both GVHD and GVL after alloSCT from HLA-
matched or partially HLA-matched donors. Preclini-
cal studies have provided insight into the mechanisms
of development of both GVL and GVHD in these
settings, and have suggested possible strategies for sep-
aratingGVL fromGVHD.The use of in vitro selected
specific T cell responses holds promise for enhancing
GVL reactivity without inducing or aggravating
GVHD. This overview will discuss preclinical studies
that illustrate mechanisms that can induce GVL reac-
tivity in the absence of severe GVHD, as well as
clinical strategies for analyzing and manipulating
T cell responses in humans that will permit infusion
of T cell populations that selectively mediate GVL re-
activity. The role of antigen-specific CD81 responses
as well as the role of CD41 T cells in this selective
induction of GVL reactivity will be discussed.ANTIGEN PRESENTING CELLS (APCS) AND
THE INDUCTION OF GVL RESPONSES
After HLA-matched alloSCT, donor-derived
CD41 and CD81 T cells must recognize specific pep-
tides presented by HLA molecules on the leukemic
target cells to exert an antitumor effect [3,4]. Most
donor-derived T cells that react with antigens pre-
sented on the recipient’s leukemic cells are unlikely
to have been exposed to those antigens in the donor
environment, and are therefore likely to derive from
the donor’s naive T cell repertoire [5]. To develop an
effective antitumor immune response, these T cells
must be primed by professional APCs in vivo or in
vitro [6]. The cells that serve as APCs in this context
include DCs, B cells, and macrophages, but recipient’s
leukemic cells may in some patients also express or
acquire an APC phenotype. In vitro and in vivo obser-
vations have indicated that malignant CML cells can
function as APCs and directly prime an antileukemic
T cell response of significant magnitude [7].
In the early posttransplant period, recipient-
derived APCs that survive the conditioning regimen
may directly present endogenously processed antigens,
resulting in the development of a GVL response if the
genes encoding the antigens are coexpressed by the
APC and themalignant cells. The inflammatory milieu
created by the conditioning regimen will upregulate
expression of costimulatory molecules on APCs and
responding immune cells, leading to amplification of
the antihost response. Tissue damage in the presence
of activated APC will lead to crosspresentation of
many recipient alloantigens that are expressed on dif-
ferent recipient tissues, which may lead to severeGVHD, particularly affecting tissues that contain
large numbers of APCs. Therefore, at the time of
transplant, damage to the (micro) environment of the
host can predispose to an undesired skewing toward
GVHD, despite codevelopment of GVL activity [8].
Gradual replacement of host hematopoiesis by
cells of donor origin, including donor-derived APCs,
creates a setting in which donor antihost responses de-
velop in the absence of profound inflammatory trig-
gers and lymphopenia. Consequently, the balance
between GVHD andGVLmay gradually shift in favor
of GVL activity. T cell depletion of the graft followed
by delayed administration of donor T cells may allow
the development of potent GVL activity and subse-
quent complete remissions without clinically signifi-
cant GVHD, particularly in the setting of CML.
However, in other, more aggressive malignancies,
early relapses after transplantation have illustrated
the need for alternative approaches to generate GVL
reactivity early after transplantation. Moreover, if
host hematopoiesis is completely replaced by cells of
donor origin, and the malignant cells do not acquire
an APC phenotype, postponed administration of
donor T cells may not efficiently trigger an immune
response against malignant cells. Under these circum-
stances, the initiation of GVL activity by donor T cells
requires their priming by donor APCs that can
crosspresent antigens expressed on the recipient’s
malignant cells. Studies in murine models have dem-
onstrated that indirect presentation of this type does
occur after allogeneic transplantation, but it is less
clear how effective this process is in humans [8,9].
The observation of late-onset GVHD developing after
the conversion to complete donor-derived hematopoi-
esis suggests that this phenomenon also occurs in
humans. Irradiation of tumor sites or coadministration
of chemotherapy or inflammatory cytokines may
increase crosspresentation of antigens derived from
malignant cells, or may activate the malignant cells
to acquire an APC phenotype, thereby increasing the
likelihood that an antitumor immune response will
develop. These preclinical and clinical studies demon-
strate that the in vivo environment, including the tumor
microenvironment, the existence of an inflammatory
milieu, and the presence of appropriate APC subsets,
strongly influences the likelihood that a specific GVL
response will develop.CD81 T CELLS MEDIATING SELECTIVE GVL
CD81 T lymphocytes recognize small peptides,
typically 8 to 11 amino acid residues in length, which
are derived from proteasome-mediated degradation
of cellular proteins and are presented by MHC class
I molecules on the surface of most nucleated cells.
The peptides presented by MHC class I molecules
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mic, and membrane proteins, and consequently, the
ensemble of different peptides collectively presented
on the cell surface—the MHC class I ‘‘peptidome’’—
comprises at least several thousand distinct peptides.
Although donors for alloSCT are typically selected
for genetic identity with the recipient at the loci that
encode MHC class I and II molecules, donor/recipi-
ent nonidentity at loci outside the MHC leads to sig-
nificant differences in the peptides that are presented
by MHCmolecules on donor and recipient cells. Pep-
tides presented in MHC molecules on recipient but
not donor cells can be recognized by donor CD81
T cells, and can initiate immune responses that medi-
ate both GVL and GVHD. Such peptides are func-
tionally defined as minor histocompatibility antigens
(mHAg).
There is evidence to suggest that the range of tis-
sues in which a given gene is expressed—and thus the
range of tissues in which a mHAg encoded by that
gene can be presented on the cell surface—influences
the extent to which CD81 T cell responses against
that antigen contribute to GVL, GVHD, or both.
CD81 T cells specific for mHAgs that are encoded
by hematopoietic-specific genes and selectively pre-
sented on recipient hematopoietic cells including the
leukemic cells—hematopoietic-specific mHAgs—may
selectively mediate GVL activity but little or no
GVHD. The HA-1 mHAg encoded by the KIAA0223
gene is arguably the best characterized and conse-
quently the prototypic mHAg with hematopoietic-
specific expression [10]. CD81 cytotoxic T cell clones
recognizing hematopoietic-specific mHAgs can inhibit
the growth of clonogenic leukemic cells in vitro [11],
and can prevent the engraftment of human AML in
immune-deficient nonobese diabetic/severe combined
immunodeficiency (NOD/SCID) mice [12], suggesting
that themHAgs they recognize are expressed on the pu-
tative leukemic stem cell. There is compelling rationale,
therefore, for the development of therapeutic strategies
that aim to exploit or manipulate CD81 T cell re-
sponses against hematopoietic-specific mHAgs. Ap-
proaches to enhancing the CD81 response to specific
mHAgs include active immunization of the donor or
of the recipient with mHAg peptide-based vaccines, as
well as adoptive transfer of donor-derived mHAg-
specific CD81 T cells that have been selected and
expanded ex vivo. Adoptive therapy with CD81 T cell
clones recognizing mHAg expressed in recipient hema-
topoietic cells but not in recipient fibroblasts has already
been explored in the clinic [13]. Clinical responses were
observed, but were transient because of the limited
persistence of adoptively transferred cells in vivo. Unex-
pected pulmonary toxicity because of expression in lung
tissue of the mHAg recognized by the adoptively trans-
ferred T cells was also observed, demonstrating that
selecting T cells for adoptive therapy based solely onreactivity in vitro with hematopoietic cells but not
fibroblasts is not a sufficiently stringent criterion to
ensure the safety of such an approach.
Although CD81mHAg-specific T cells play a crit-
ical role in both initiating and sustaining the GVL
effect, CD81 T cells recognizing nonpolymorphic
antigens presented by MHC class I molecules on
recipient tumor cells may also contribute to GVL
activity. The mHAg-specific CD81 and CD41 T cell
responses that occur after MHC-matched alloSCT
may enable and recruit CD81T cell responses to pep-
tides that are (1) derived from normal self proteins
such as proteinase-3 and WT1 and (2) aberrantly
expressed in recipient tumor cells. Proteinase-3 and
elastase, the major constituents of the primary azuro-
phil granules of normal promyelocytes as well as
AML and CML blasts, both contain the PR1 peptide
that binds to HLA-A*0201. CD81 T cells specific
for the PR1 peptide presented by HLA-A*0201 have
been detected in peripheral blood of HLA-A*02011
CML patients who achieved remission after MHC-
matched alloSCT [14,15]. CD81 HLA-A*0201-
restricted responses to WT1 have been observed in
HLA-A*02011 ALL patients after alloSCT, and their
appearance was correlated with clearance of molecular
markers of residual disease [16]. These clinical obser-
vations have generated interest in manipulating
CD81 immunity to PR1, WT1, and similar proteins
to enhance the GVL effect.
Data from several recent studies suggest that donor
CD81 T cell responses against recipient tumor-
specific antigens are also primed in the immunogenic
environment of alloSCT and may contribute to GVL
activity against myeloid and lymphoid leukemia, and
myeloma. Regression of multiple myeloma in several
patients who underwent DLI was associated with the
appearance and selective expansion of myeloma-
specific CD81 T cells [17]. Antigens encoded by
cancer-testis (CT) genes including NY-ESO-1 and
the MAGE and SSX gene families are often expressed
in advanced or poor-prognosis myeloma [18-20], and
CD81 T cell responses to these CT antigens have
been detected in patients after alloSCT [21]. Donor
CD81 T cell responses to NY-ESO-1 and other CT
antigens have also been detected in patients trans-
planted for MDS and AML [21]. Expression of CT
genes can be induced in malignant myeloid cells by
the hypomethylating agents azacitidine and decitabine
[22] raising the prospect that epigenetic modulation
with these drugs could be effectively combined with
adoptive T cell therapy targeting CT antigens to treat
myeloid leukemia’s. CD81 responses against tumor-
specific antigens also probably contribute to GVL
against chronic lymphoid leukemia. In a recent study,
complete remission of CLL after nonmyeloablative
MHC-matched alloSCT was closely associated with
appearance of donor-derived tumor-specific CD81
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gens recognized by these tumor-specific T cells is in
progress.CD41 T CELLS AS MEDIATORS OF GVL
REACTIVITY
Much of the research aimed at dissecting the GVL
effect at the cellular and molecular level has focused on
the role of donor CD81 T cells recognizing recipient
mHAgs. This bias was based on the common percep-
tion that CD81 cells are the primary effector cells of
the GVL effect, and responsible for most of the antitu-
mor activity. According to this view, CD41T cells are
required only to provide help for the induction and
maintenance of CD81-mediated immunity. However,
CD41 T cells can exhibit direct cytolytic reactivity
against leukemic cells in vitro, and leukemia-reactive
CD41 cells have been isolated from patients experi-
encing profound GVL reactions after DLI [24]. Clin-
ical studies showing that depletion of CD81 T cells
from a stem cell graft or DLI can reduce the incidence
and severity of GVHD without strongly compromis-
ing the GVL effect [25,26] have provided compelling
additional support for a role for CD41 cells as GVL
effectors.
Recent studies have identified several mHags
recognized by HLA class II-restricted CD41 cells
that were isolated from patients who received DLI
for posttransplant relapse and experienced antitumor
responses in the absence of clinically significant
GVHD [27-29]. These antigen-identification studies
utilized several different techniques, including screen-
ing of cDNA expression libraries and genetic linkage
analysis. Similar to the HLA class I-restricted mHAgs,
the class II-restricted mHAgs identified in these stud-
ies are derived from proteolytic degradation of endog-
enous proteins that are encoded by polymorphic
genes, and are presented on the cell surface in complex
with HLA-DR, -DQ, or -DP molecules. The mHAg-
specific CD41 T cells exhibited helper functions, but
also possessed directly cytolytic activity against leuke-
mic precursor cells expressing the appropriate HLA
class II molecules. Analysis of the range of tissues in
which the mHAg-encoding genes are expressed re-
vealed a variety of expression profiles. Some of the
genes are selectively expressed in hematopoietic cells,
whereas others show expression in both hematopoietic
and nonhematopoietic tissues. Despite the broad ex-
pression of some of the mHAg-encoding genes, the
mHAg-specific CD41 T cell clones recognized only
hematopoietic cells. The lack of recognition of nonhe-
matopoietic cells despite expression in those cells of
the mHAg-encoding genes is explained by the lack of
HLA class II expression in most nonhematopoietic
cells under noninflammatory conditions.Constitutive expression of HLA class II molecules
is mainly observed in subsets of normal as well as
malignant hematopoietic cells, and therefore CD41
T cells specific for HLA class II-restricted mHAgs
preferentially recognize hematopoietic cells. Several
studies have demonstrated, however, that high fre-
quencies of recipient mHag-specific CD41 T cells in
the early posttransplant period correlated with the
onset of clinical GVHD. In the early phase after trans-
plantation, tissue damage from the conditioning regi-
men, high pathogen load, and vigorous homeostatic
proliferation of donor T cells in the setting of lympho-
penia may cause profound release of proinflammatory
cytokines. Collectively, these factors will lead to the
induction of HLA class II molecule expression on non-
hematopoietic target tissues, particularly those con-
taining high numbers of activated professional APCs,
resulting in strong activation of donor T cells. In
some patients, a general cytokine ‘‘storm’’ in the early
posttransplant period will induce expression of HLA
class II molecules on a broad range of recipient tissues,
and in this setting donor CD41 T cells specific for re-
cipient mHAgs can amplify GVHD. However, it may
be possible to develop therapeutic strategies for selec-
tively enhancing GVL by delayed administration of
donor CD41 T cells recognizing recipient mHAgs
later during the posttransplant period, after the acute
inflammatory processes have resolved.
The observations that constitutive expression of
HLA class II molecules is limited to hematopoietic
cells, and that these molecules are expressed on nonhe-
matopoietic tissues only in the setting of inflammation,
allow exploitation of the alloreactive properties of
CD41 T cells that recognize major histocompatibility
differences to mediate selective GVL activity. This has
particular relevance for unrelated donor/recipient
transplant pairs, because of the fact that genetic dispar-
ity at the HLA-DP locus is present in up to 80% of
‘‘fully’’ HLA-matched unrelated donor/recipient pairs
(that is, donor/recipient pairs that are matched for
HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ).
Donor CD41T cell responses against mismatched re-
cipient HLA-DP alleles may significantly contribute
to GVL activity in the unrelated setting. Indeed,
a polyclonal, recipient HLA-DP-specific immune re-
sponse developed in a patient with B cell chronic lym-
phocytic leukemia who achieved complete remission
after DLI [30]. In vitro studies suggested that the
tumor-specific T cell response that occurred in the ab-
sence of clinically significant GVHD, was mediated
solely by the donor CD41 T cells recognizing the re-
cipient’s mismatched HLA-DP molecules. In this pa-
tient DLI was administered late after transplantation,
in the absence of clinically apparent inflammation,
when HLA-DP may have been primarily expressed
on recipient’s hematopoietic cells. Although this case
is instructive, studies of other patients who received
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nonidentical donors have demonstrated that CD41
donorT cell responses recognizing the recipient’s mis-
matched HLA-DP molecules occurred in association
with clinically evident GVL and GVHD [31]. The
potential therapeutic benefit of specifically targeting
recipient HLA class II-restricted mHAgs, or mis-
matched recipient HLA-DP molecules, with selective
infusion of purified donor CD41 T cells, or CD41
T cells specific for defined recipient minor or major
HLA class II antigens, will need to be evaluated in pro-
spective clinical trials.
Recent studies in the NOD/scid mouse model of
human ALL demonstrated that infusion of highly
purified CD41 T cells, in the absence of any contam-
inating or residual CD81 T cells, could effectively
eradicate the leukemic cells in vivo [32]. CD41 T cells
specific for HLA-DR, HLA-DQ, and HLA-DP con-
tributed to the antileukemic effect, which was medi-
ated in part by direct cytolytic activity of the infused
CD41 T cells against the leukemic cells. Moreover,
‘‘crosstalk’’ between the CD41 T cells and the leuke-
mic cells triggered the acquisition by the leukemic cells
of an APC-like phenotype in vivo, thereby making
them more susceptible to killing by CD41 T cells. If
the profound HLA class II-specific immune response
occurs in the presence of a high tumor load, this may
cause intense local inflammation that results in upre-
gulation of HLA class II expression on nonhemato-
poietic tissues, and consequently to the development
of GVHD. These results again illustrate that the deli-
cate balance between GVL and GVHD is determined
not only by the antigenic specificity of the responding
T cells, but also by specific features of the immune re-
sponse that ensues. Manipulating both the specificity
of the effector cells and the conditions within the tu-
mor environment will likely be required for optimal
exploitation of the therapeutic potential of posttrans-
plant adoptive therapy with donor CD41 T cells.CONCLUSION
Following fully or partiallyHLA-matched alloSCT,
donor CD81 and CD41 T cell responses may result in
specific GVL reactivity in the absence of GVHD. The
delicate balance between GVL and GVHD is deter-
mined by several factors, including the susceptibility of
the malignant cells to T cell recognition, the presenta-
tion of recipient antigens that allow recognition by do-
nor T cells, as well as the specific conditions within the
tumor environment. These factors can either support
or suppress the development of an effective antileukemic
T cell response. Adoptive transfer of T cells selected for
specific recognition of recipient hematopoietic cells
without recognition of recipient nonhematopoietic tis-
sues may lead to specific GVL responses after alloSCT.However, it may also be possible to exploit T cell re-
sponses directed against more broadly expressed recipi-
ent antigens to enhance GVL selectively without
inducing or aggravatingGVHD.This will require care-
ful manipulation of the in vivo microenvironment,
including the inflammatory state of the patient and the
magnitude of the response, and selection of the appro-
priate subsets of antigen-specificTcells that have potent
antileukemic activity and can proliferate and develop
into a durable antitumor memory T cell response.ACKNOWLEDGMENTS
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